Frontage Laboratories

Frontage operates unified global quality systems that apply the same SOPs to every site. A sponsor's lead candidate can move from medicinal chemistry through DMPK, safety toxicology, and Phase I clinical-trial-material manufacturing without leaving Frontage's quality envelope. The firm credits this architecture with compressing timelines and lowering the data-reconciliation risk that arises when multiple CROs hand off work at each gate.

The firm maintains 25 sites: 12 in North America, 12 in China, and one in Europe. The dual US-China footprint lets sponsors run parallel discovery campaigns or GLP toxicology studies in both regions under the same quality framework. Frontage explicitly markets this as a way to reduce costs and accelerate IND filings by matching a program's stage to the appropriate geography without changing vendors.

Frontage functions as both a CRO and a CDMO. Its CMC division handles formulation development, analytical services, and clinical-trial-material manufacturing for NCE, 505(b)(2), and ANDA products through Phase III. This means a sponsor can use Frontage for everything up to and including the drug product used in first-in-human studies, rather than contracting a separate CDMO after preclinical work wraps.

Frontage runs a dedicated agrochemical division that provides biological, chemical, and regulatory support within a GLP-compliant facility. The firm frames this as a natural extension of its analytical and toxicology capabilities, applying the same quality infrastructure to crop-protection products that it uses for small-molecule drugs.

The firm announced co-CEO promotions in 2024, signaling a governance shift that likely splits operational and strategic responsibilities at the top. During the same window, it added a vice president of clinical services and new global discovery leadership, suggesting a deliberate push to integrate its clinical and preclinical arms more tightly under shared executive oversight.